UniHA approves framework agreement covering over 1,500 French public hospitals, facilitating the purchase of Swoop® AI-powered portable MRI systems over...
UniHA approves framework agreement covering over 1,500 French public hospitals, facilitating the purchase of Swoop® AI-powered portable MRI systems over...
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October...
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire /...
Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlookWARSAW, Ind., Oct. 09,...
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company...
FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company...
TOKYO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter...
Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is...
Study Demonstrated a Sensitivity of 100% and Specificity of 95%Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular...
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
New subscription-based platform empowers a community of Swoop® system users worldwide to access advanced tools in support of imaging research...
The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials...
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a...
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /...
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- As per the latest market research by Business Market Insights (BMI), the research...
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections...
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections...